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Abstract
Background: Inguinal hernia repair is one of the most frequently performed procedures in Switzerland (15'000/year). The most
common complication postoperatively is development of chronic pain in up to 30% of all patients irrespective of the operative
technique.
Methods/Design: 264 patients scheduled for an inguinal hernia repair using one of three procedures (Lichtenstein, Barwell and
TEP = total extraperitoneal hernioplasty) are being randomly allocated intra-operatively into two groups. Group I patients
receive a local injection of 20 ml Carbostesin® 0.25% at the end of the operation according to a standardised procedure. Group
II patients get a 20 ml placebo (0.9% Saline) injection. We use pre-filled identically looking syringes for blinded injection, i.e. the
patient, the surgeon and the examinator who performs the postoperative clinical follow-ups remain unaware of group allocation.
The primary outcome of the study is the occurrence of developing chronic pain (defined as persistent pain at 3 months FU)
measured by VAS and Pain Matcher® device (Cefar Medical AB, Lund, Sweden).
The study started on July 2006. In addition to a sample size re-evaluation three interim analyses are planned after 120, 180 and
240 patients had finished their 3-months follow-up to allow for early study termination.
Discussion: Using a group sequential study design the minimum number of patients are enrolled to reach a valid conclusion
before the end of the study.
To limit subjectivity, both a VAS and the Pain Matcher® device are used for the evaluation of pain. This allows us also to compare
these two methods and further assess the use of Pain Matcher® in clinical routine.
The occurrence of chronic pain after inguinal hernia repair has been in focus of several clinical studies but the reduction of it
has been rarely investigated. We hope to significantly reduce the occurrence of this complication with our investigated
intervention.
Trial Registration: Our trial has been registered at ClinicalTrials.gov. The trial registration number is: [NCT00484731].
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Background
Inguinal hernia repair is one of the most frequently per-
formed procedures in Switzerland (about 15'000 cases per
year) [1]. The most common complication postopera-
tively is development of chronic pain in up to 30% of
patients irrespective of the operative technique [2-7].
Callesen et al. [3] found the persistence of pain at 1 and 4
weeks after surgery to be a predictive factor on the devel-
opment of chronic pain. Courtney et al. [8] concluded
that chronic pain persists in most patients who report
pain up to 3 months after hernia repair. Surgical proce-
dures like the ilioinguinal neurectomy recently described
by Mui et al. [9] lead to a significant reduction of chronic
pain but also to numbness and discomfort in the groin
region. Whereas Ravichandran et al. [10] in contrast
showed no significance of the elective division of the ilio-
inguinal nerve.
In addition to the problems caused by hernia surgery the
objective evaluation of the postoperative pain is limited.
The Visual Analogue Scale (VAS) is often used in similar
study settings and is well known as "gold standard" for
eliciting pain. However Lundeberg et al. [11] reported the
VAS is a questionable instrument for the measurement of
pre- and postoperative pain because it remains very sub-
jective and is based on varying previous pain experience.
Hence the VAS has a misleading precision because of an
imprecise individual determination of the VAS of about ±
20 mm (DeLoach et al.) [12].
An alternative option for measuring pain is the recently
developed Pain Matcher® by Cefar Medical AB, Lund, Swe-
den. This perceptual matching device uses electrical stim-
ulation against which the patient has to match the
perceived pain with nonvisualized endpoints. It seems to
be more objective and reduces recording bias. The device
has been tested for safety and reliability in several clinical
trials [13-16] and has not been used so far in the field of
hernia surgery.
The use of local compared to general anaesthesia in hernia
surgery has only been described by O'Dwyer et al. [17] not
investigating the outcome on the development of chronic
pain after hernia repair. A positive effect of postoperative
single shot or continuous infiltration with local anaesthet-
ics on acute postoperative pain has been described by sev-
eral authors [18-20].
We designed a randomized placebo controlled triple
blinded trial to investigate the effect of an additional
intra-operative infiltration with local anaesthesia on the
development of chronic postoperative pain. Because of
incertainty of data used for sample size estimation, a
sequential design data analysis for early study stopping
along with revision of sample size is applied. As Aasvang
and Kehlet [21] pointed out there is an urgent need for the
treatment opportunities and assessment of chronic pain
after herniorrhaphy. We hope to contribute with this
study to this common problem after hernia repair.
Methods/Design
Patients are recruited in the outpatients and the emer-
gency department. If they meet the inclusion criteria (see
next section), informed consent is obtained and the oper-
ation is planned. According to our randomization process
the patient is automatically either allocated to the verum
or control group by the sequence of the consecutive num-
bered and block randomized syringes. An overview of the
patient recruitment and follow-up is presented in Figure
1.
Inclusion and exclusion criteria
Adult patients (≥ 18 years) with primary or recurrent sin-
gle or double sided symptomatic but not incarcerated
inguinal hernias with an elective hernia repair are
included. No other interventions (i.e. umbilical hernia)
are allowed. Written informed consent needs to be
obtained.
Patients with legal incompetence, pregnant and nursing
women, patients with presence or history of active malig-
nancy or systemic diseases, under immunosuppressive
treatment, with systemic or severe local inflammation or
infection, with wound healing disorders and with physi-
cal or mental incapacity, which makes it impossible to
obtain informed consent are excluded. As pacemakers
interfere with the electrical stimulation of the Pain
Matcher® and vice versa patients with pacemakers or other
implanted electrical devices were also excluded.
Surgical Methods
Allowed standardized surgical procedures for the hernia
repair are Lichtenstein [22,23], Barwell [24] and TEP [25].
These procedures for the hernia repair are performed
directly or under the supervision by used to test the effi-
cacy of the local infiltration. The operation is performed
by a general surgery consultant or, a senior resident or
under supervision of one of them. The hierarchical posi-
tion and individual surgeon experience in the field of
regarding inguinal hernia repair (i.e. number of per-
formed operations) is documented.
Anaesthesiological Methods
After the repair of the inguinal hernia the verum Bupi-
vacain (Carbostesin® 0.25%) or the placebo Saline (0.9 %)
is injected close to the nerves of the groin region following
a standardized procedure (Figure 2). The injection starts 2
fingers below and 2 fingers medial the spina iliaca anerior
superior on the lateral end of the incision (Figure 3). Ten
ml of the substance will be injected fan-shaped laterallyBMC Surgery 2007, 7:22 http://www.biomedcentral.com/1471-2482/7/22
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patient flow according to the revised CONSORT-statement Figure 1
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and 4 ml medially of the cranio-lateral puncture. The
medio-caudal puncture is located directly above the pubic
tubercle on the medial end of the incision. 4 ml of the
substance will be fan-shaped injected lateral and 2 ml
medial of the puncture.
Randomization & Blinding
The randomization based on a computer-generated block
randomization sequence is performed in 1:1 ratio
between the investigational and the control arm. The
pharmacy of our hospital provides equal looking syringes
of placebo and verum numbered according to the rand-
omization sequence that is kept confidential. Patient, sur-
geon and the doctor performing examinations during
follow-up visits will not know about treatment allocation
for each patient, which leads to this unique triple blinded
study design.
The randomization code will be broken only in the fol-
lowing circumstances:
- for all patients at the completion of the final data analy-
ses
- for individual patients following the occurrence of
adverse events requiring immediate knowledge of treat-
ment allocation for the safety of the patient.
The Pain Matcher Device
The Pain Matcher® (Cefar Medical AB, Lund, Sweden; Fig-
ure 4) is a perceptual matching device unit that gives con-
stant current stimulation which is controlled by a
microprocessor that provides rectangular pulses with a
frequency of 10 Hz and an amplitude of 10 mA. It is pro-
grammed to give a constant current stimulation despite
variable skin resistance (e.g., influenced by sweating and
anxiety of the subject) up to 13 kΩ. The intensifying of
guide for the injection of the verum/placebo Figure 3
guide for the injection of the verum/placebo.
anatomy of the groin region Figure 2
anatomy of the groin region.BMC Surgery 2007, 7:22 http://www.biomedcentral.com/1471-2482/7/22
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stimulation is achieved by successively increasing the
pulse width from 0 to a possible maximum of 450 µs in
increments of 7.5 µs, up to a total of 60 steps. The electri-
cal charge per second is extremely low and varies through
the different steps from 1.5 to 45 µC. The reached value
(0–100) is directly related to the pulse width and is dis-
played on a liquid crystal display screen. The contact sur-
face area, and hence the resulting current density, is
ensured by a certain minimum finger pressure against the
electrode; this is achieved by instructing the patient to
hold the electrode box between the thumb and the index
finger in a horizontal position requiring a certain mini-
mum, predetermined pressure. A further increase in elec-
trode pressure does not improve the functionality of the
Pain Matcher®.
Primary Outcome
According to Courtney et al. [8] who concluded that
chronic pain persists in most patients who report persist-
ent pain at 3 months after hernia repair, we chose the
occurrence of chronic pain (persistent pain at 3 months
FU measured by VAS and Pain Matcher®) in the operated
groin region for our primary outcome.
Secondary Outcomes
Level of Pain
- Pain Matcher®
- VAS
- Areas of hyperalgesia, hypaesthesia
Hospitalization
- Length of stay (days)
- ASA-Classification
- Beginning of mobilisation (days)
- Removal of drainage (days)
Function
- Return to work or normal activity (days and %)
- Quality of life (SF36)
Amounts of follow-up and recorded parameters are sum-
marized in Table 1.
Hypothesis
We hypothesise a 50% reduction of the occurrence of
postoperative chronic pain after 3 months in the interven-
tion group receiving intra-operative infiltration with local
anaesthetic after an inguinal hernia repair compared with
patients in the control group receive placebo infiltration.
Sample size & power calculation
Required sample sizes and interim analysis data for both
groups were estimated using the computer programme
East® Version 4 (Cytel Inc., 675 Massachusetts Ave. Cam-
bridge, MA02139 USA). Sample size estimation was based
on a risk of occurrence of chronic pain without local
anaesthetic infiltration of 30% in patient having inguinal
hernia surgery (Poobalan et al. [4]).
Considering a 0.05 two-sided significance level, a power
of 80%, a detectable risk reduction of 50% and an alloca-
tion ratio of 1:1, 120 patients per group were estimated.
Assuming a dropout rate of 10% (declining, exclusion,
loss to follow-up, etc.) in the study, 132 patients per
group(264 patients) are going to be enrolled.
Group sequential design and interim analysis
To allow for early stopping of the trial, a group sequential
analysis is performed. The first of three interim analyses
will be performed as soon as 120 patients (60 per group)
have had their 3-month follow-up. Further interim analy-
ses are planned after 180 and 240 patients (final analysis).
We will use a χ2-test to test the null-hypotheses. The anal-
ysis will be performed on the 'intention-to-treat' basis, i.e.
patients will be analyzed in the groups to which they were
randomized.
Stopping rules
The randomization code will not be broken for the
interim analyses, unless a stopping rule is met. At each
interim analysis, the following stopping rules will apply:
1. A χ2-test demonstrates that one treatment is superior
over the other (i.e. rejection of the null-hypothesis) OR,
Pain Matcher® Figure 4
Pain Matcher®BMC Surgery 2007, 7:22 http://www.biomedcentral.com/1471-2482/7/22
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2. If statistical significance cannot be likely reached with
the maximum allowable number of patients for the study,
which is set to 200 per arm (i.e. acceptance of the null-
hypothesis).
Table 2 shows the threshold z-values for the χ2-test at each
interim analysis. Boundaries for the interim analyses are
calculated on the model developed by O'Brien & Fleming
[26-32] (Figure 5).
If a stopping criterion has not been reached, the trial will
continue until the next interim analysis. If the trial is
stopped after an interim analysis, all patients already
enrolled in the trial will be followed up to the last planned
visit.
Sample size re-estimation
Independent of the sequential design, a sample size re-
estimation will be conducted before the first interim anal-
ysis, and the number of patients required for each interim
analysis will be adapted accordingly. The study will be
continued until the next interim analysis or terminated if
more than 200 patients per arm are additionally needed
to show a significant result.
All interim analyses will be performed by an independent
organization without the knowledge of the randomiza-
tion code. The revision of the sample size will be made
available to the investigators, if applicable. No other
results will be provided to the investigators, unless a stop-
ping rule is fulfilled and the study has to be terminated.
Ethical approval
The study was approved by the local ethical committee of
the Kanton Luzern on the 1st of May 2006 and the first
amendment on the 26th  of February 2007 (approval
number 585).
Discussion
Chronic pain after inguinal hernia repair is a common
complication that needs to be addressed. This rand-
omized placebo controlled triple blinded designed trial
should provide conclusive results regarding the effective-
ness of intra-operative use of local anaesthesia in mitigat-
ing this problem.
Using a group sequential study design, a minimum
number of patients will be recruited until interim results
suggest continuing the study became unethical. This
approach has been described first by Pocock [33,34] who
provided methodological guidelines already in the late
Table 1: Follow-up and recording of data
Baseline FU 1 FU 2 FU 3 FU 4
Consultation Intra-/post-OP 2 weeks 1 month 3 months 12 months
General data
- Patients data
- Informed consent
Anaesthesiological data
Surgical intervention
Edverse events
Primary outomes:
- VAS
- Pain Matcher®
Secondary outcomes:
9
9
9 9
9
9 9 9 9 9
9 9 9 9 9 9
9 9 9 9 9 9
9 9 9 9 9 9BMC Surgery 2007, 7:22 http://www.biomedcentral.com/1471-2482/7/22
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70's and early 80's. O'Brien and Fleming [26] described
tests with conservative stopping boundaries for interim
analyses with a decision rule. Methods determining the
sample size needed for the group sequential test to attain
the desired power were described by Fleming, Harrington
and O'Brien [35] and by Wang & Tsiatis [36]. As this study
design should be attractive to clinical researchers reducing
the number of unnecessarily involved human being in
clinical trials it has been used rarely since the mentioned
publications in the 80's! A search in Pubmed [37] returns
439 randomized controlled trials using a group sequential
design out of 215'249 since 1980, only 2 ‰ in the last 27
years!
We are using the VAS and Pain Matcher® for the evaluation
of pain which allows us to compare these two methods
and confirm the good results of the recently published
studies [13-16] using the Pain Matcher® in clinical routine.
Publishing this study protocol we contribute to good,
honest and ethically correct clinical research already
called for in 1999 by Chalmers and Altman [24]. This step
should be included in official guidelines like the CON-
SORT-Statement and other authors should be convinced
to publish their study protocols fighting against poor and
ethically unfair research in medicine!
List of abbreviations
ASA american society of anaestesiologists
CONSORT Consolidated Standards of Reporting Trials
FU follow up
RCT randomised controlled trial
SF36 short form 36
TEP total extraperitoneal hernioplasty
VAS visual analog scale
Table 2: Threshold z-values for the χ2-test at each interim analysis
Interim analyses Number of patients Reject H0 if z ≥ Accept  H0 if z < Reject H0 if p ≤
1 120 -2.9626 2.9626 0.0031
2 180 -2.359 2.359 0.0183
3 = final analysis 240 -2.0141 2.0141 0.044
boundaries and estimated example of the interim analysis Figure 5
boundaries and estimated example of the interim analysis.BMC Surgery 2007, 7:22 http://www.biomedcentral.com/1471-2482/7/22
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